title: [Distribution of hepatitis C virus genotypes among the hemodialysis population in the province of Alicante].
abstract: Hepatitis C virus (HCV) genotypes are irregularly distributed among the different geographic area and groups at risk.
  
  
  OBJECTIVE
  To study the different HCV genotypes and subtypes of hemodialyzed patients from Alicante.
  
  
  METHODS
  We studied 640 patients on haemodialysis (HD) and we determined the RNA-HCV and the genotypes in the 120 patients with antibodies against HCV (HCV-Ab). We compared the results with the genotypes of 1,370 patients from other groups at risk in the same geographic area.
  
  
  RESULTS
  RNA-HCV was not found in the serum in 15% (18/120) of the patients on HD who were HCV-Ab positive. Prevalence of the different genotypes in the 102 patients with positive viral RNA was the following: 1b: 56.8% (58/102), 1a: 19.6% (20/102), 3: 17% (17/102), 2a-2c: 1.9 (2/102), 2b: 0.9% (1/102) 4: 2.9 (3/102), 5: 0.9% (1/102). In conclusion, the genotype 1b was the most frequent in the patients studied in all these areas, and was the same as in the rest of the country. This genotype has been associated with the most severe hepatic disease and poor response to treatment, affecting the prognosis of these patients. The most frequent genotypes in HD in Alicante were 1b, 3 and 1a. HCV genotypes distribution among the HD units was not uniform in the different geographic areas. HCV genotypes distribution in the HD population is similar to other groups at risk from the same geographic area.
authors.affiliation: Servicio de Nefrología del Sanatorio Perpetuo Socorro, Plaza Dr. Gómez Ulla, 15 03013 Alicante.
authors.forename: M D
authors.initials: MD
authors.lastname: Arenas
authors.forename: C
authors.initials: C
authors.lastname: Muñoz
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Payá
authors.forename: R
authors.initials: R
authors.lastname: Jover
authors.forename: J J
authors.initials: JJ
authors.lastname: Egea
authors.forename: M T
authors.initials: MT
authors.lastname: Gil
authors.forename: F
authors.initials: F
authors.lastname: Martín
authors.forename: F
authors.initials: F
authors.lastname: Sarró
authors.forename: A
authors.initials: A
authors.lastname: Soriano
authors.forename: A
authors.initials: A
authors.lastname: Luna
authors.forename: J
authors.initials: J
authors.lastname: Olivares
authors.forename: A
authors.initials: A
authors.lastname: Reyes
authors.forename: E
authors.initials: E
authors.lastname: Muñoz del Bustillo
authors.forename: C
authors.initials: C
authors.lastname: del Pozo
authors.forename: V
authors.initials: V
authors.lastname: Valverde
authors.forename: M
authors.initials: M
authors.lastname: Perdiguero
authors.forename: A
authors.initials: A
authors.lastname: Araque
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000453:epidemiology / Q000821:virology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012367:RNA, Viral / Q000097:blood / Q000235:genetics / Q000302:isolation & purification*; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D014766:Viremia / Q000453:epidemiology / Q000821:virology
chemical_list: D012367:RNA, Viral